Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + irinotecan + apatinib as second-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2000032038Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, irinotecan and Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall survival. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
camrelizumabirinotecanRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000032038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032038.